Phrixus Pharmaceuticals, Inc.

Ann Arbor, MI 48104

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $2.39MM
First Award Date 09/30/07
Most Recent Award Date 06/18/12

Key Personnel

Last Name Name Awards Contact
Markham Bruce E. Markham 6

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 06/18/12 - 05/31/13

DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and heart failure (HF) in Duchenne muscular dystrophy (DMD) patients. DMD is a debilitating and fatal genetic disease, with an incidence of 1:3500 live...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/11 - 03/31/13

DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystrophy (DMD). Phrixus Pharmaceuticals Inc. is also developing P-188 for the treatment of acute decompensated heart failure (HF) and has an open IND u...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-09-081
Budget: 08/19/10 - 03/31/13

DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxygen (ischemia) results in tissue damage, the direct involvement of membrane injury in the progression of ischemic HF is a relatively novel concept. T...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 01/15/09 - 12/31/09

DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and Becker Muscular Dystrophy (MD). Dr. Joe Metzger and colleagues (Yasuda et al., 2005) demonstrated that P-188 seals microscopic membrane tears in c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 02/01/08 - 01/31/09

DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement therapy for end stage renal disease (ESRD). PD as a renal replacement therapy is the method of choice for about 10% of dialysis patients in the US (approx...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/30/07 - 03/31/09

DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of these patients, over 40% have a defect in the ability of the heart muscle to relax which prevents the heart from filling with blood normally (dias...